Medico Remedies Ltd: Strong Q1 FY27 Growth Driven by Sales Surge

Revenue from operations for Q1 FY27 reached Rs 69.40 crore, an 81.4% increase from Rs 38.25 crore in Q1 FY26. Profit after tax stood at Rs 2.52 crore, up 38.5% from Rs 1.82 crore in the prior year period.

Reader Takeaway: Stellar YoY growth in revenue and profit, alongside board stability, provides positive signals. However, sequential profit decline needs monitoring.

What just happened

Medico Remedies Ltd announced its standalone financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company reported a significant 81.4% year-on-year increase in revenue from operations, reaching Rs 69.40 crore compared to Rs 38.25 crore in the same period last year. Profit Before Tax (PBT) grew by 37.4% to Rs 3.34 crore from Rs 2.43 crore, and Profit After Tax (PAT) saw a 38.5% rise to Rs 2.52 crore from Rs 1.82 crore.

Why this matters

This robust year-on-year performance indicates a strong demand for Medico Remedies' products and effective operational execution. The substantial revenue growth is a positive sign for shareholders, suggesting an expanding market presence. The re-appointment of key management personnel, including the Chairman and Whole-Time Director, Mr. Haresh Mehta, and Whole-Time Director, Mr. Rishit Mehta, for a three-year term starting September 18, 2026, ensures leadership stability and continuity.

The backstory

Medico Remedies Ltd is involved in the manufacturing of pharmaceutical formulations. The company has been working on expanding its product portfolio and market reach.

What changes now

With the re-appointments, the company benefits from continued experienced leadership, which is crucial for executing its growth strategies. The approved increase in remuneration for the Managing Director, Mr. Harshit Mehta, signals the board's confidence in his leadership and performance.

Risks to watch

While year-on-year growth is impressive, the filing notes a sequential decline in profitability when compared to the quarter ended March 31, 2026 (Q4 FY26). Additionally, there has been a significant shift in geographical sales mix, with domestic sales increasing substantially while international sales have decreased compared to the previous quarter. Investors will need to monitor if this trend continues and its impact on overall profitability.

Peer comparison

(No peer comparison data provided in the filing.)

Context metrics (time-bound)

In Q1 FY27, Medico Remedies reported sales of Rs 26.34 crore within India and Rs 42.70 crore outside India. This contrasts with Q4 FY26, where domestic sales were Rs 2.74 crore and international sales were Rs 53.64 crore. This marks a significant pivot towards the domestic market.

What to track next

Investors should closely watch the company's performance in the upcoming quarters to see if the strong year-on-year growth momentum is sustained and how the shift in geographical sales impacts the company's overall revenue and profit margins.